High Proliferation Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Early Breast Cancer

BACKGROUND. In the neoadjuvant setting, changes in the proliferation marker Ki67 are associated with primary endocrine treatment efficacy, but its value as a predictor of response to chemotherapy is still controversial. PATIENTS AND METHODS. We analyzed 262 patients with centralized basal Ki67 immun...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Alba, Emilio, Lluch, Ana, Ribelles, Nuria, Anton-Torres, Antonio, Sanchez-Rovira, Pedro, Albanell, Joan, Calvo, Lourdes, García-Asenjo, Jose Antonio Lopez, Palacios, Jose, Chacon, Jose Ignacio, Ruiz, Amparo, De la Haba-Rodriguez, Juan, Segui-Palmer, Miguel A., Cirauqui, Beatriz, Margeli, Mireia, Plazaola, Arrate, Barnadas, Agusti, Casas, Maribel, Caballero, Rosalia, Carrasco, Eva, Rojo, Federico
Formato: Artigo
Idioma:Inglês
Publicado: AlphaMed Press 2016
Assuntos:
Breast Cancer
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4746087/
https://ncbi.nlm.nih.gov/pubmed/26786263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2015-0312
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares